EXEL•benzinga•
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance
Summary
Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga